Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;470(1):199-210.
doi: 10.1007/s00424-017-2030-y. Epub 2017 Oct 10.

Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers

Affiliations
Review

Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers

Angelo Corti et al. Pflugers Arch. 2018 Jan.

Abstract

Chromogranin A (CgA), a secretory protein released in the blood by neuroendocrine cells and neurons, is the precursor of various bioactive fragments involved in the regulation of the cardiovascular system, metabolism, innate immunity, angiogenesis, and tissue repair. After the original demonstration that circulating CgA can serve as a biomarker for a wide range of neuroendocrine tumors, several studies have shown that increased levels of CgA can be present also in the blood of patients with cardiovascular, gastrointestinal, and inflammatory diseases with, in certain cases, important diagnostic and prognostic implications. Considering the high structural and functional heterogeneity of the CgA system, comprising precursor and fragments, it is not surprising that the different immunoassays used in these studies led, in some cases, to discrepant results. Here, we review these notions and we discuss the importance of measuring total-CgA, full-length CgA, specific fragments, and their relative levels for a more thorough assessment of the pathophysiological function and diagnostic/prognostic value of the CgA system.

Keywords: Cardiovascular diseases; Catestatin; Chromogranin A; Inflammatory diseases; Neuroendocrine tumors; Serpinin; Vasostatins.

PubMed Disclaimer

References

    1. Am Heart J. 2006 Nov;152(5):927.e1-6 - PubMed
    1. Regul Pept. 2006 Jul 15;135(1-2):78-84 - PubMed
    1. J Rheumatol. 2008 Jan;35(1):91-9 - PubMed
    1. Ann Oncol. 2001;12 Suppl 2:S153-7 - PubMed
    1. Regul Pept. 2004 Mar 15;117(3):219-27 - PubMed

Publication types

LinkOut - more resources